Coastlands Capital LP, a significant shareholder in ADIAL PHARMACEUTICALS, INC. (NASDAQ:ADIL), executed a new acquisition of the company's common stock on June 29, 2026. The investment firm purchased 25,000 shares at a price of $2.60 per share, resulting in a total transaction value of $65,000. This purchase activity increased Coastlands Capital LP's indirect holdings in Adial Pharmaceuticals, bringing its total ownership position to 373,322 shares of common stock. The stock currently trades at $2.79, slightly above the purchase price, though the company has faced significant headwinds with a 53% decline over the past six months. According to InvestingPro analysis, ADIL appears undervalued at current levels, with the stock showing signs of recent momentum despite longer-term challenges. The company maintains a FAIR financial health rating, and InvestingPro offers 11 additional exclusive tips for investors evaluating this micro-cap pharmaceutical stock. Coastlands Capital LP is classified as a ten percent owner of Adial Pharmaceuticals.
According to the filing, Coastlands Capital LP serves as the investment adviser to Coastlands Capital Partners LP. Matthew Perry is identified as the control person for Coastlands Capital LP and its related entities. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
In other recent news, Adial Pharmaceuticals Inc. announced the closing of a $32 million financing tranche as part of a previously disclosed private placement, which could total up to $64 million. This financing was led by Coastlands Capital and included participation from other institutional investors. The funds were partly used to convert outstanding notes from Adial's acquisition of Azora Therapeutics, a $32 million deal that brought Azora's lead asset, AT177, into Adial's pipeline. Additionally, Adial Pharmaceuticals has filed a new U.S. utility patent application for its investigational drug AD04, aimed at treating Alcohol Use Disorder, with hopes of securing patent protection through at least 2045. Adial PharmaFollowAnalyze ADILIncluded in our AI-picked strategies·Review strategies2.71▲+0.150(+5.86%)Real-time Data·10:49:42·USD1D1W1M6M1Y5YMaxCreated with Highcharts 11.4.830/0616:0018:0019:0001/072.42.52.62.72.8Analyze ADILIn a strategic move, Adial also applied for the FDA's Commissioner's National Priority Voucher Pilot Program to expedite the review of its AD04 product. Meanwhile, Lucid Capital Markets initiated coverage on Adial Pharmaceuticals with a buy rating, citing the potential of its colitis drug, and set a price target of $6.00 per share over the next 12 months. These developments reflect Adial's ongoing efforts to expand its product pipeline and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Should you invest $2,000 in ADIL right now?ProPicks AI evaluates ADIL alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ADIL is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?See More Stocks